ӳ��ý

Cancer Program

In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.

Dubrot J, Du PP, Lane-Reticker SK, et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol. 2022;23(10):1495-1506. doi:10.1038/s41590-022-01315-x

Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.

Bondeson DP, Paolella BR, Asfaw A, et al. Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. Nat Cancer. 2022. doi:10.1038/s43018-022-00360-7

An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML.

Lin S, Larrue C, Scheidegger NK, et al. An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. Cancer Discov. 2022;12(2):432-449. doi:10.1158/2159-8290.CD-20-1851

Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer.

Ouspenskaia T, Law T, Clauser KR, et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat Biotechnol. 2022;40(2):209-217. doi:10.1038/s41587-021-01021-3

PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.

Khadka P, Reitman ZJ, Lu S, et al. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nat Commun. 2022;13(1):604. doi:10.1038/s41467-022-28198-8

Somatic and germline genomic alterations in very young women with breast cancer.

Waks AG, Kim D, Jain E, et al. Somatic and germline genomic alterations in very young women with breast cancer. Clin Cancer Res. 2022. doi:10.1158/1078-0432.CCR-21-2572

Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma.

Labaki C, Bakouny Z, Sonpavde G, Choueiri TK, Van Allen EM. Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma. Eur Urol Oncol. 2022. doi:10.1016/j.euo.2022.01.004

Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.

Stover EH, Oh C, Keskula P, et al. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. Prostate. 2022. doi:10.1002/pros.24305

Sparse dictionary learning recovers pleiotropy from human cell fitness screens.

Pan J, Kwon JJ, Talamas JA, et al. Sparse dictionary learning recovers pleiotropy from human cell fitness screens. Cell Syst. 2022. doi:10.1016/j.cels.2021.12.005

Massively parallel phenotyping of coding variants in cancer with Perturb-seq.

Ursu O, Neal JT, Shea E, et al. Massively parallel phenotyping of coding variants in cancer with Perturb-seq. Nat Biotechnol. 2022. doi:10.1038/s41587-021-01160-7